Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis - Wikidata - awgldk - TriplyDB

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

http://www.wikidata.org/entity/Q35583380

about

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP II The role of the LDL receptor in apolipoprotein B secretion.Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33 The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice Molecular mechanisms underlying the effects of statins in the central nervous system.Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins.Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease.Evaluation of plasma cholestane-3β,5α,6β-triol and 7-ketocholesterol in inherited disorders related to cholesterol metabolism.One year experience in the treatment of familial hypercholesterolaemia with simvastatin Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice.Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials.Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease.Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel tri Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development.The metabolism of lipoprotein (a): an ever-evolving story.Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe.Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.Wolman disease and its treatment.Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes.Fast progression of liver damage in lysosomal acid lipase deficiency.Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects.Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs Association of LIPA Gene Polymorphisms With Obesity-Related Metabolic Complications Among Severely Obese Patients

P2860

Q24812046-CA13FD4F-D447-4E8B-BE21-C4DE2A8E148A Q28569109-8F28EAFB-B449-472B-A839-C6B2E2C96820 Q33900333-077743C6-9CDE-4225-8179-64B6DBB408E4 Q33939089-0484C206-FEAA-48CA-B1C3-350B9F50CA71 Q33940346-C093672E-9DF1-4DAC-971C-882BE7C0590C Q34137441-403A2AE1-7C18-46F9-B6BE-573665F578B3 Q34260272-4B288B0E-0B32-4B66-9512-C390BB3F3D92 Q34356070-26FCADB2-9FD0-4AE4-93E8-45AB55AA1276 Q34685463-D539BF5C-A496-4405-B645-C2B0A67236DB Q34729472-79A74BAC-E031-4351-98D2-03CECF2E4D43 Q35182920-B0A5D10C-2211-4464-937B-2440220B5F5A Q36617431-80610BC1-22B7-4164-9139-5EABB884D6E5 Q36682706-DC830861-BF41-4FBD-9975-9E5C96E5DE17 Q36743546-C5714D20-CA9A-4C10-9F5E-EDEC59395D6F Q36745074-B3F7784E-82D5-40F0-ABC3-E7FEBF16347C Q36806626-A39F1F5F-1F3D-4B4C-988C-8E11B6B851E6 Q37057100-239C566C-4344-4895-87B9-6E0F980CE9BD Q37604513-A773E1A2-933A-4523-B115-044404F2A16C Q37705070-3E55BAC6-3500-48C3-B145-5FF137FF9550 Q37717441-FA7730DF-CA1B-42E8-B15D-0607A40C1CFA Q38655614-9CEF92FB-0B68-4F42-A097-2E10969A549B Q38891202-DD45B777-47A3-486D-99AF-C42145CC25E3 Q39136059-761C8979-7797-4604-806A-2175CDE9BA66 Q40549567-4BF8310A-709F-490A-9AAB-1C4573EE8331 Q42482221-4FBB55E5-5FE5-4E9C-96A3-E042D7408B09 Q44272184-16A750C5-F0F9-4633-9010-869A3ECD846B Q45868093-D7826AC3-8BEF-488B-91B2-ED3C7DE8B2FA Q46703453-B205C977-834F-4CDE-BDFE-98D2774BF0CD Q55017020-9CD1D6D2-7931-43E6-8A15-474C8EB9E48A Q57012269-DA14584C-CD2D-449E-A00E-F8003C5EC2B6 Q57316293-5C010FBD-22B1-499F-9C7B-A84568EEBC83

P2860

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

http://www.wikidata.org/entity/Q35583380

description

1987 nî lūn-bûn

@nan

1987年の論文

@ja

1987年論文

@yue

1987年論文

@zh-hant

1987年論文

@zh-hk

1987年論文

@zh-mo

1987年論文

@zh-tw

1987年论文

@wuu

1987年论文

@zh

1987年论文

@zh-cn

name

Suppression of apolipoprotein ...... of apolipoprotein B synthesis

@ast

Suppression of apolipoprotein ...... of apolipoprotein B synthesis

@en

type

label

Suppression of apolipoprotein ...... of apolipoprotein B synthesis

@ast

Suppression of apolipoprotein ...... of apolipoprotein B synthesis

@en

prefLabel

Suppression of apolipoprotein ...... of apolipoprotein B synthesis

@ast

Suppression of apolipoprotein ...... of apolipoprotein B synthesis

@en

P1433

Q35583380-57DA5F3C-4F64-4DA8-AF6C-E48774A857FC

P1476

Q35583380-1ACB31DC-C9FA-4D3B-AEF0-8F34DA7B6D00

P2093

Q35583380-1013DB0C-52B3-453E-85D0-90F4ACA4DC9A

Q35583380-6584A9CF-24CB-4D95-8AA4-1E10A0752C04

Q35583380-667F9388-4D81-4360-ABE8-F8AB8222CDF4

Q35583380-6AC18D5D-0203-4312-A706-ED5D2EBCEB34

Q35583380-7BDEF6D7-67F8-4A07-A385-BF355175671A

P2860

Q35583380-0D2CE2DF-CBE6-40E7-9B3F-7E485A96C6D7

Q35583380-0FEE66CB-E742-4636-8514-020ACE49DB6A

Q35583380-14051F00-7161-4430-A4F5-F4F20791FE8F

Q35583380-1BB1A7DC-2E76-4B8B-8907-3650EB7DE498

Q35583380-1F9C19F8-C892-40D7-8108-A5FB6987C951

Q35583380-20FFB215-BFDB-443A-BA2F-58969A63A66C

Q35583380-244B43F4-09A1-46A6-9FAF-E28668E37434

Q35583380-5A69E7A6-E514-4FB0-9875-B3C5F474E41F

Q35583380-6102952E-16F3-4AA3-9EB9-CD4E37292373

Q35583380-6BF15ED0-2EEB-43B1-9E02-F4A8665E727A

P304

Q35583380-F49C9FA6-E379-422A-97B8-C179844C2C2A

P31

Q35583380-974A65C9-ADB5-4790-A553-D8D3C045097F

P356

Q35583380-F07EA179-4145-444A-823F-94B7ACBE9CFF

P407

Q35583380-3A34A4D2-4AC7-40B3-A73C-B8F734B1A53F

P433

Q35583380-6ACE9E85-C34C-4E6F-800B-C54A4428AEC0

P478

Q35583380-AFB29DD8-27BD-4EC7-8F92-9BF58B136F83

P577

Q35583380-3ECA08F7-83E8-4866-A230-F4A8031C4C31

P5875

Q35583380-9D8D1865-7185-4822-B9BF-5AA7A06F9185

P698

Q35583380-FF3A4713-AB13-45C8-861E-C55602C9F827

P932

Q35583380-9296F3B5-654F-48BF-9F55-7EA662EA2DA3

P356

P1433

Journal of Clinical Investigation

P1476

Suppression of apolipoprotein ...... of apolipoprotein B synthesis

@en

P2093

H N Ginsberg

http://www.w3.org/2001/XMLSchema#string

M P Short

http://www.w3.org/2001/XMLSchema#string

N A Le

http://www.w3.org/2001/XMLSchema#string

R J Desnick

http://www.w3.org/2001/XMLSchema#string

R Ramakrishnan

http://www.w3.org/2001/XMLSchema#string

P2860

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia

Plasma mevalonate as a measure of cholesterol synthesis in man

The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia.

Generalized xanthomatosis with calcified adrenals.

Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.

Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog

A biochemical and morphologic study of very low density lipoproteins in carbohydrate-induced hypertriglyceridemia.

The metabolism of the apoprotein of plasma low density lipoprotein in familial hyperbetalipoproteinaemia in the homozygous form.

P304

1692-1697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI113259

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

1987-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

19480458

http://www.w3.org/2001/XMLSchema#string

P698

3680522

http://www.w3.org/2001/XMLSchema#string

P932

442441

http://www.w3.org/2001/XMLSchema#string